Casablanca – Morocco is entering a new phase in the development of its regulated medical cannabis sector, as authorities, healthcare institutions, researchers, and pharmaceutical stakeholders intensify efforts to expand the therapeutic use of cannabis-derived products and strengthen the industry’s scientific foundations.
The latest discussions within the sector indicate that Morocco has largely completed the initial stages of building a legal and regulatory framework governing cannabis cultivation, processing, manufacturing, and distribution for medical and pharmaceutical purposes. Attention is now increasingly shifting toward encouraging clinical applications, supporting scientific research, and integrating cannabis-based treatments into healthcare practices.
Recent industry assessments have highlighted the progress achieved in pharmaceutical manufacturing. More than 140 cannabis-derived medical products have now been developed and officially registered through the country’s regulatory system. These products are available through a network of more than 600 licensed sales and distribution points, reflecting the expansion of a regulated supply chain designed to support medical use.
The growth of the sector follows the implementation of legislation that legalized and regulated cannabis cultivation for medical, pharmaceutical, and industrial purposes. Since then, efforts have focused on creating an organized value chain capable of generating economic opportunities while maintaining strict oversight of production and commercialization activities.
Officials involved in the sector have emphasized that Morocco now possesses both the legal framework and the production capacity required to support a modern medical cannabis industry. Significant advances have been achieved not only in cultivation but also in industrial processing and pharmaceutical manufacturing, allowing the country to move beyond the traditional production of raw materials and toward higher-value products.
Despite these achievements, healthcare experts acknowledge that the actual therapeutic use of cannabis-derived medicines remains at an early stage. While supply has expanded and regulatory conditions have been established, the integration of these products into routine medical practice is progressing more gradually.
This situation has led to growing calls for stronger cooperation between healthcare professionals, scientific associations, academic institutions, and regulatory authorities. Specialists argue that broader medical adoption will require additional clinical studies, treatment protocols, physician training, and evidence-based guidelines capable of supporting safe and effective prescribing practices.
Medical cannabis is increasingly being examined as a complementary therapeutic option across a range of medical fields. Areas under discussion include neurological disorders, chronic pain management, gastrointestinal diseases, rheumatologic conditions, oncology, intensive care medicine, and certain pediatric applications. However, experts stress that any expansion of medical use must remain guided by scientific evidence and regulatory safeguards.
A major focus of current initiatives involves strengthening research capacity. Participants in recent sector meetings have advocated for increased support for clinical and pharmaceutical research aimed at evaluating the effectiveness, safety, and appropriate medical indications of cannabis-based treatments.
Among the proposals under consideration are the creation of national research programs, the establishment of dedicated databases for scientific publications, and the introduction of incentives to encourage innovation and academic research in the field. Such measures are viewed as essential for generating locally relevant scientific evidence and supporting the long-term development of the sector.
Training and education have also emerged as priorities. Universities and healthcare institutions are exploring the introduction of specialized educational programs focused on medical cannabis. These initiatives aim to provide physicians, pharmacists, and other healthcare professionals with the knowledge required to understand therapeutic indications, prescribing practices, dosage considerations, and potential side effects.
The inclusion of medical cannabis topics within medical, pharmaceutical, and allied health curricula is increasingly being discussed as a means of preparing future healthcare professionals for the evolving landscape of cannabis-based therapies. Continuing education programs for practicing healthcare workers are also expected to play an important role.
In addition to healthcare objectives, the development of the medical cannabis industry carries significant economic implications. The regulated cultivation of cannabis has created new opportunities for agricultural producers, particularly small-scale farmers participating in authorized production systems.
Industry stakeholders believe that expanding the range of medical applications could contribute to the sustainability of the sector by increasing demand for legally produced cannabis and encouraging further investment in processing and pharmaceutical manufacturing. This, in turn, could help strengthen local value creation and support employment across different stages of the supply chain.
The sector’s evolution also reflects broader efforts to position Morocco as a regional center for pharmaceutical production and health-related innovation. By combining agricultural expertise, industrial capabilities, scientific research, and regulatory oversight, the country is seeking to build a comprehensive ecosystem capable of supporting both domestic healthcare needs and future export opportunities.
At the same time, policymakers continue to emphasize the importance of maintaining strict controls over production, distribution, and medical use. Regulatory authorities have repeatedly highlighted that the development of the sector must be accompanied by rigorous monitoring mechanisms, quality standards, and patient safety measures.
Several recommendations emerging from recent discussions call for the establishment of national treatment protocols, standardized clinical guidelines, patient monitoring systems, and improved public awareness regarding the legitimate medical uses of cannabis-derived products. These measures are intended to promote responsible use while ensuring that healthcare decisions remain based on scientific evidence.
As Morocco moves into this next phase of development, the focus appears to be shifting from building production capacity toward expanding therapeutic applications and strengthening scientific knowledge. The existence of more than 140 registered medical products and a nationwide network of over 600 licensed distribution points demonstrates the progress already achieved.
The coming years are expected to determine how effectively the country can translate this industrial and regulatory foundation into broader healthcare benefits, increased research activity, and sustainable economic opportunities. For now, the medical cannabis sector is emerging as one of the most closely watched areas of Morocco’s pharmaceutical and healthcare development strategy.
